MedTrace Logo

Recombinant Adeno-associated Virus Administration for Patients With Menkes Syndrome

NCT05507996 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-11-30

No results posted yet for this study

Summary

It is a single-center, open, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of recombinant adeno-associated virus administration for patients with Menkes syndrome.

Conditions

  • Menkes Syndrome

Interventions

DRUG

Recombinant adeno-associated virus administration

The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.

Sponsors & Collaborators

  • Kunming Hope of Health Hospital

    lead OTHER

Principal Investigators

  • Li Li · Kunming Hope of Health Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-18
Primary Completion
2022-11-23
Completion
2022-11-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05507996 on ClinicalTrials.gov